

Press Release



November 20, 2018
Stem Cell & Device Laboratory Co., Ltd.
<http://scad-kyoto.com/>

SCAD will present at the 9th Annual Conference on Biomolecular Screenology in Tokyo

SCAD will present a poster at the 9th Annual Conference on Biomolecular Screenology to be held on November 30, 2018, in Tokyo, Japan. Our poster, titled

“3D-Cell Device with Aligned and Multilayered Tissues for Predictive Drug Safety Applications”

features the application of our physiologically relevant cardiac and neural microtissues for the prediction of drug toxicity on human biology in vitro. We look forward to meeting you at the poster sessions.

General information

Official website: <https://screenology.org/index.php/english>

Date: November 30, 2018

Place: Tower Hall Funabori, Tokyo

About SCAD

SCAD is a biotech company offering cell product and service innovations that accelerate drug discovery and development. We are committed to the development, manufacturing, and commercialization of the next generation cells and cell devices for predictive, in vitro drug safety and efficacy applications. SCAD's proprietary fiber-based cell culturing technologies and expertise enables the creation of physiologically relevant microtissues that ensure consistent levels of maturity, functionality, and stability. Our flagship product is the SCAD-MT™, a ready to use 3D cell culture platform already validated for cardiac and neural microtissues. Besides, we offer a wide range of development services that suit the cell-based assay needs of the pharmaceutical industry. As a company, we strive towards the realization of “*a new society created by stem cells*” by enabling the faster delivery of efficacious and safe medicines to patients.

For more information

Stem Cell & Device Laboratory, Inc. (SCAD) Management

Section: Mrs. Sonoko Chiaki

TEL: 075-744-1114; E-mail: scad.info@scad-kyoto.com